FA
COGT icon

Forefront Analytics’s Cogent Biosciences COGT Stock Holding History

Forefront Analytics’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,015
Closed -$83.5K – 45
2025
Q1 		$83.5K Buy
14,015
+255
+2% +$2K 0.1% 40
2024
Q4 		$107K Buy
13,760
+3,739
+37% +$37.3K 0.05% 58
2024
Q3 		$108K Sell
10,021
-5,606
-36% -$54.6K 0.05% 61
2024
Q2 		$132K Sell
15,627
-3,648
-19% -$27.7K 0.06% 60
2024
Q1 		$130K Sell
19,275
-707
-4% -$4.37K 0.06% 57
2023
Q4 		$117K Buy
+19,982
New +$153K 0.06% 59

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Forefront Analytics's COGT Position: Q2 2025 in Review

Forefront Analytics sold out of Cogent Biosciences (COGT) in Q2 2025, closing a stake of 14,015 shares — an estimated $83.5K sold.

Forefront Analytics first reported a position in COGT in Q4 2023 and held it in 6 quarters. The position peaked at $132K in Q2 2024. 180 funds tracked by Wall St. Rank hold COGT as of Q2 2025.

  • Forefront Analytics reported no remaining Cogent Biosciences position as of Q2 2025 after selling out during the quarter.
  • Forefront Analytics sold 14,015 Cogent Biosciences shares in Q2 2025, an estimated $83.5K.
  • Forefront Analytics first reported a position in Cogent Biosciences in Q4 2023 and held it in 6 quarters.
  • Forefront Analytics's Cogent Biosciences position peaked at $132K in Q2 2024.
  • 180 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2025.

Based on Forefront Analytics's 13F filing for Q2 2025, filed 24 Jul 2025.